People with diabetes are more prone to developing Staphylococcus aureus, a leading cause of infections and death associated ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

You probably think “antibiotic resistance” means that a bacterial infection can’t be cured by any antibiotics. But the FDA ...

However, their value in the management of uncomplicated skin infections is not yet clearly defined. This literature review discusses various topical antibiotic treatment options for uncomplicated ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Antibiotics are indispensable for treating bacterial infections. But why are they sometimes ineffective, even when the bacteria are not resistant? In their latest study, researchers challenge the ...

Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections. The drug – a combination of beta-lactam antibiotic aztreonam with beta ...

Photodynamic inactivation using curcumin shows promise in reducing antibiotic resistance diversity in Staphylococcus aureus, ...

Penicillin was discovered in 1928 and has been used to treat various infections since the 1940s. Amoxicillin is a semi-synthetic penicillin that became available in 1972. Amoxicillin and penicillin ...

Antiperistaltic agents and opiates should be avoided. In general, strive to use antibiotics covering a spectrum no broader than necessary and narrow the antibiotic spectrum of treatment after ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...